FDA reveals systemic underreporting of clinical trial data: 30% of mandated results missing amid regulatory enforcement gaps

Indigenous epistemologies view clinical trial data as a collective resource, not a proprietary asset, and would frame non-disclosure as a violation of intergenerational trust and ecological balance. The Māori principle of *whanaungatanga* (relationship) would demand transparency not just to regulators but to affected communities, including trial participants and their descendants. Traditional African communal ethics, such as Ubuntu ('I am because we are'), would reject the commodification of health data that underpins pharmaceutical secrecy.

The 30% non-reporting rate echoes historical patterns of corporate secrecy in health, such as the 50-year delay in acknowledging the harms of leaded gasoline or the 30-year suppression of asbestos data by manufacturers. The opioid crisis demonstrated how pharmaceutical companies systematically buried trial data on addiction risks, leading to over 500,000 overdose deaths in the U.S. alone. Regulatory capture in the FDA dates back to the 1980s, when the Prescription Drug User Fee Act (PDUFA) tied agency funding to industry payments, creating perverse incentives for leniency.

Cross-culturally, the tension between profit and transparency is framed differently: in Japan, the concept of *meiwaku* (avoiding harm to others) would pressure pharmaceuticals to disclose risks proactively, while in Scandinavian social democracies, universal healthcare systems inherently demand public access to clinical data. The contrast with U.S. neoliberal healthcare, where data is treated as a marketable commodity, highlights how cultural values shape regulatory outcomes. In India, the principle of *dharma* (duty) would require corporations to prioritize public health over shareholder returns.

Meta-research consistently shows that non-reporting of clinical trials inflates perceived drug efficacy by 25-30% and underestimates harms, a bias documented in 2015 by the Cochrane Collaboration. The FDA's own analysis likely underestimates the problem, as it relies on self-reported data from sponsors and lacks independent audits of trial registries. The *AllTrials* campaign, supported by 800+ medical journals, has demonstrated that selective reporting distorts evidence-based medicine, leading to avoidable patient harm and wasted research funding.

Artistic and spiritual traditions often depict secrecy as a form of violence: in Greek myth, Cassandra's curse of truth-telling yet non-belief mirrors the fate of whistleblowers in pharmaceuticals. Buddhist teachings on *Right Speech* would condemn data suppression as a violation of ethical conduct, while Indigenous oral traditions warn of generational curses for withholding knowledge. The Hindu concept of *Rita* (cosmic order) would frame clinical trial transparency as a moral duty to maintain balance in the universe of health and disease.

If current trends continue, the FDA's failure to enforce reporting could lead to a 20% increase in preventable adverse drug reactions by 2035, costing $150 billion annually in U.S. healthcare. Scenario modeling suggests that mandatory third-party audits of trial registries could reduce non-reporting to <5% within a decade, saving 10,000 lives annually. Alternative models, such as the European Medicines Agency's (EMA) proactive disclosure policies, demonstrate that transparency can coexist with innovation without stifling drug development.

Marginalized communities—particularly Black, Indigenous, and low-income participants in Global South trials—are disproportionately harmed by non-reporting, as their data is often the first to be suppressed to protect corporate interests. The 2018 *Sponsor-Investigator* scandal in Nigeria, where Pfizer concealed deaths in a meningitis trial, exemplifies how racialized bodies are treated as disposable in clinical research. Whistleblowers like Peter Buxtun, who exposed the Tuskegee Syphilis Study, are systematically silenced, while industry-funded 'experts' dominate regulatory panels, ensuring that marginalized voices are excluded from policy decisions.